Forskning ved Københavns Universitet - Københavns Universitet

Forside

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. / Thurison, Tine; Lomholt, Anne F; Rasch, Morten G; Lund, Ida K; Nielsen, Hans J; Christensen, Ib J; Høyer-Hansen, Gunilla; Lomholt, Anne Fog.

I: Clinical Chemistry, Bind 56, Nr. 10, 01.10.2010, s. 1636-40.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Thurison, T, Lomholt, AF, Rasch, MG, Lund, IK, Nielsen, HJ, Christensen, IJ, Høyer-Hansen, G & Lomholt, AF 2010, 'A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer', Clinical Chemistry, bind 56, nr. 10, s. 1636-40. https://doi.org/10.1373/clinchem.2010.144410

APA

Thurison, T., Lomholt, A. F., Rasch, M. G., Lund, I. K., Nielsen, H. J., Christensen, I. J., ... Lomholt, A. F. (2010). A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clinical Chemistry, 56(10), 1636-40. https://doi.org/10.1373/clinchem.2010.144410

Vancouver

Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, Christensen IJ o.a. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clinical Chemistry. 2010 okt 1;56(10):1636-40. https://doi.org/10.1373/clinchem.2010.144410

Author

Thurison, Tine ; Lomholt, Anne F ; Rasch, Morten G ; Lund, Ida K ; Nielsen, Hans J ; Christensen, Ib J ; Høyer-Hansen, Gunilla ; Lomholt, Anne Fog. / A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. I: Clinical Chemistry. 2010 ; Bind 56, Nr. 10. s. 1636-40.

Bibtex

@article{b325fb9a077b421d936f4a694608662d,
title = "A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer",
abstract = "The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.",
author = "Tine Thurison and Lomholt, {Anne F} and Rasch, {Morten G} and Lund, {Ida K} and Nielsen, {Hans J} and Christensen, {Ib J} and Gunilla H{\o}yer-Hansen and Lomholt, {Anne Fog}",
year = "2010",
month = "10",
day = "1",
doi = "10.1373/clinchem.2010.144410",
language = "English",
volume = "56",
pages = "1636--40",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry, Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

AU - Thurison, Tine

AU - Lomholt, Anne F

AU - Rasch, Morten G

AU - Lund, Ida K

AU - Nielsen, Hans J

AU - Christensen, Ib J

AU - Høyer-Hansen, Gunilla

AU - Lomholt, Anne Fog

PY - 2010/10/1

Y1 - 2010/10/1

N2 - The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.

AB - The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.

U2 - 10.1373/clinchem.2010.144410

DO - 10.1373/clinchem.2010.144410

M3 - Journal article

C2 - 20802096

VL - 56

SP - 1636

EP - 1640

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10

ER -

ID: 34090054